Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Luci
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Beta
- -2.08
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -11.57
Financials
Net Income
$-2.58MEBITDA
$-2.58MFree Cash Flow
$-2.49MEPS (diluted)
$-0.49Shares Outstanding (diluted)
5.32M+1014.2%Operating Expenses
$2.63MCash & Debt
$9.65MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-7.97M | $-5.32 |
| 2024 | $0.00 | $-14.10M | $-17.59 |
| 2023 | $0.00 | $-14.58M | $-23.01 |
| 2022 | $0.00 | $-12.09M | $-22.36 |
| 2021 | $0.00 | $-12.75M | $-24.96 |
| 2020 | $0.00 | $-4.60M | $-9.28 |
| 2019 | $0.00 | $-5.93M | $-12.00 |
Valuation
ACXPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (6)
- Newsprnewswire.com·10d ago·Neutral
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update STATEN ISLAND, N.Y., Nov. 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for serious or life-threatening bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2026.
View source ↗ - Newsprnewswire.com·27d ago·Neutral
…cial Results on November 12, 2026 Conference Call and Provide Business Update STATEN ISLAND, N.Y., Oct. 26, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for serious and life threatening bacterial infections, announced today that the Company will discuss its third quarter 2026 financial results on Thursday, November 12, 2026 at 8:00 am ET before the U.S. financial markets op…
View source ↗ - Newsprnewswire.com·54d ago·Positive
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in the broader patient population for the treatment of acute CDI, has potential to shift the paradigm of treatment and prevention of rCDI
View source ↗ - Newsprnewswire.com·97d ago·Negative
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration progr
View source ↗ - Newsseekingalpha.com·100d ago·Positive
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·100d ago·Neutral
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2026.
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-0.40 per share
Typical surprise -5.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.49 vs $-0.38miss
- Fri, Aug 14$-0.53 vs $-0.38miss
- Tue, May 12$-0.62 vs $-0.59miss
- Fri, Mar 13$-0.31 vs $-1.01beat
- Wed, Nov 12$-1.23 vs $-1.61beat
- Tue, Aug 12$-1.89 vs $-2.00beat
Estimates and results for ACXP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACXP officers and directors.
- Bought
- $615k
- Sold
- —
21 trades
0 trades
- Scodari Joseph Cbought
- Scodari Joseph Cbought
- Sailer Carlbought
- Sailer Carlbought
- Luci David Pbought
- Luci David Pbought
- Donohue James J.bought
- Donohue James J.bought
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACXP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
